Results 41 to 50 of about 11,492 (193)
Comparison of MAFLD and NAFLD Characteristics in Children
, 2023 Background & aims: An international panel proposed a diagnostic framework for metabolic-associated fatty liver disease (MAFLD) in children. The aim was to compare the clinical features of MAFLD and nonalcoholic fatty liver disease (NAFLD) in children.
Hui Wang +3 more
core +1 more source
The role of adipokines in the disease of metabolic-associated fatty liver disease
Tungs’ Medical Journal, 2023 According to the World Health Organization’s reports, the prevalence of fatty liver disease is increasing worldwide, and that of type 2 diabetes in adults aged over 18 years has increased from 4.7% in the 1980s to 8.5% in 2014.
Chieh Chen
doaj +1 more source
New therapeutic options for metabolic‐associated steatotic liver disease
British Journal of Clinical Pharmacology, EarlyView.An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley +1 more source
Clinical characteristic by presence of MAFLD.
, 2022 Clinical characteristic by presence of MAFLD.
Akihiko Ikura (4112230) +6 more
core +1 more source
Drugs in Context, 2022 COVID-19 increases the risk of atrial fibrillation (AF) and thrombotic complications, particularly in severe cases, leading to higher mortality rates. Anticoagulation is the cornerstone to reduce thromboembolic risk in patients with AF.
Juan José Cerezo-Manchado +5 more
doaj +1 more source
Association between RBC count and MAFLD status.
, 2022 Association between RBC count and MAFLD status.
Guowei Zhou (2124553) +2 more
core +1 more source
, 2021 Background: Metabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related HCC.
Regueiro González-Barros, José Ramón +9 more
core +1 more source
Redefining Fatty Liver Disease: How Updated Nomenclature Reshapes Clinical Laboratory Diagnostics
iLABMED, EarlyView.The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction‐associated steatotic liver disease (MASLD) reorients laboratory diagnosis from exclusion‐based rules toward metabolic and inflammatory biomarkers. This review compares their diagnostic criteria, epidemiology, insulin resistance mechanisms, imaging, and key laboratory ...
Ran Wei +3 more
wiley +1 more source
MAFLD in Obese Children: A Challenging Definition
, 2021 Background: Recently, the new definition of Metabolic (dysfunction) associated fatty liver disease (MAFLD) has gained remarkable scientific interest.
Arenella, Mattia +15 more
core +1 more source
iMeta, EarlyView.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source